Codexis Announces Expansion of Collaboration with Teva Pharmaceutical

Codexis, Inc. CDXS today announced the continued expansion of its collaboration with Teva Pharmaceutical Industries Ltd TEVA. Codexis has now successfully completed technology transfer of custom biocatalysts for manufacture of three undisclosed pharmaceutical products to Teva. Two products have been transferred to pilot manufacturing and a third to full scale commercial manufacturing. The original agreements covering development of these processes were signed in 2009. Teva is using Codexis biocatalysis technology to reengineer key process steps in the manufacture of the covered generic products. Codexis develops proprietary custom biocatalysts which can reduce pharmaceutical manufacturing development time and costs. Codexis technology is used by leading drug and chemical companies worldwide. Financial terms were not disclosed.